Contact

Let's talk.

Span is building a way to predict resistance to targeted therapy, so oncology programs can enrich and recruit trials with the right patients at the right time. Whether you develop drugs, run trials, hold data or invest, one short form reaches both founders.

Send a message

Name *

Work email *

Organization * Independent is fine

Job title optional

What would you like to explore with us? *

Applying Span to a drug program or clinical trial A data or research collaboration Investing in Span AI Something else (careers, press, general)

When are you looking to move? optional

Actively exploring now In the next 6 months Just learning for now

What are you working on, and where could Span help? *

Prefer email? Write to [email protected]. This form is protected by Cloudflare Turnstile and forwarded to a Google Form that only the founders read; it is not used for anything else.

Message sent.

Thank you. The founders read every message and will reply by email.

Before you write

Span is pre-clinical. There is no cleared assay, no prospective trial, and no patient has been treated on a Span alarm. The aim is to de-risk oncology development: read resistance to a targeted therapy early enough to change who enters a trial, and when.

The most useful first message is a specific one: the program and therapy where enrichment or recruitment is the problem, the data you hold, or the thesis you invest on. What Span is asking for is written out: the retrospective experiment for development and data teams, and the route to a first customer for investors.

The form passes a Cloudflare Turnstile spam check and is then forwarded to a Google Form, as disclosed beside the submit button. If your organisation cannot route through that, email [email protected] directly and it reaches the same two people.

Investors

Pre-clinical, two founders, a methods paper and an open benchmark. The thesis, the route to a first customer and the risk are all written down before you ask. Then ask for the deck and the paper.

Read the route first

Ask for the deck and the paper

Clinical & pharma partners

We are looking for one retrospective serial-ctDNA arm (detection calls, draw dates, a progression date) to score the change-point test against a pre-specified naive rule. No new samples, no protocol change, analysis and code returned.

The experiment, in full

Email us about a serial arm

Careers & general

Interested in the problem, or just want to learn more about what we're building? Say hello.

Get in touch

Or email [email protected].